Literature DB >> 15221940

The hypoxia-regulated transcription factor DEC1 (Stra13, SHARP-2) and its expression in human tissues and tumours.

Helen Turley1, Charles C Wykoff, Sandra Troup, Peter H Watson, Kevin C Gatter, Adrian L Harris.   

Abstract

DEC1, also known as SHARP-2 or Stra13, is an important molecule in embryonic differentiation and has recently been identified to be strongly inducible by hypoxia. Its distribution in normal human tissues and most tumour types is unknown. In the present study, a polyclonal antiserum to a 10-amino acid peptide from DEC1 has been raised. Using this antiserum, DEC1 was shown to be widely expressed in most normal human tissues, but usually only in a proportion of cells and typically with a nuclear localization. In tumours, expression was either augmented (the commonest pattern) or occasionally decreased. Similarly, in most normal tissues, low or absent expression was observed in endothelial cells, whereas in many tumour samples endothelium was usually strongly positive. In tumours, there was a striking pattern of staining seen in connection with areas of necrosis, with absence of DEC1 expression within a zone of morphologically viable cells immediately adjacent to the necrotic zone. This suggests that while DEC1 may be up-regulated by hypoxia in cancer, in more extreme hypoxia it may have a role in cell death. Its interrelationship with other hypoxically regulated molecules, such as the hypoxia-inducible factors or carbonic anhydrase IX, and differentiation of tumours now requires further investigation. Copyright 2004 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15221940     DOI: 10.1002/path.1585

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  30 in total

1.  Cellular and molecular responses of cultured neurons to stressful stimuli.

Authors:  Jun Chen; Hongna Pan; Robert H Lipsky; Anabel Pérez-Gómez; David Cabrera-Garcia; Maria Teresa Fernández-Sánchez; Antonello Novelli; Ann M Marini
Journal:  Dose Response       Date:  2011-02-22       Impact factor: 2.658

2.  Hypoxia-induced transcriptional repression of the melanoma-associated oncogene MITF.

Authors:  Erez Feige; Satoru Yokoyama; Carmit Levy; Mehdi Khaled; Vivien Igras; Richard J Lin; Stephen Lee; Hans R Widlund; Scott R Granter; Andrew L Kung; David E Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-26       Impact factor: 11.205

3.  STRA13 expression and subcellular localisation in normal and tumour tissues: implications for use as a diagnostic and differentiation marker.

Authors:  A Ivanova; S-Y Liao; M I Lerman; S Ivanov; E J Stanbridge
Journal:  J Med Genet       Date:  2005-07       Impact factor: 6.318

4.  Effect of DEC1 on the proliferation, adhesion, invasion and epithelial-mesenchymal transition of osteosarcoma cells.

Authors:  Shuai Li; Dan Peng; Zi-Qing Yin; Wei Zhu; Xuan-Tao Hu; Cong-Wei Liu
Journal:  Exp Ther Med       Date:  2020-01-17       Impact factor: 2.447

5.  Genomic and functional integrity of the hematopoietic system requires tolerance of oxidative DNA lesions.

Authors:  Ana Martín-Pardillos; Anastasia Tsaalbi-Shtylik; Si Chen; Seka Lazare; Ronald P van Os; Albertina Dethmers-Ausema; Nima Borhan Fakouri; Matthias Bosshard; Rossana Aprigliano; Barbara van Loon; Daniela C F Salvatori; Keiji Hashimoto; Celia Dingemanse-van der Spek; Masaaki Moriya; Lene Juel Rasmussen; Gerald de Haan; Marc H G P Raaijmakers; Niels de Wind
Journal:  Blood       Date:  2017-08-21       Impact factor: 22.113

6.  Error-prone translesion replication of damaged DNA suppresses skin carcinogenesis by controlling inflammatory hyperplasia.

Authors:  Anastasia Tsaalbi-Shtylik; Johan W A Verspuy; Jacob G Jansen; Heggert Rebel; Leone M Carlée; Martin A van der Valk; Jos Jonkers; Frank R de Gruijl; Niels de Wind
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-10       Impact factor: 11.205

7.  The transcription factor DEC1 (BHLHE40/STRA13/SHARP-2) is negatively associated with TNM stage in non-small-cell lung cancer and inhibits the proliferation through cyclin D1 in A549 and BE1 cells.

Authors:  Yang Liu; Liang Wang; Xu-Yong Lin; Jian Wang; Juan-Han Yu; Yuan Miao; En-Hua Wang
Journal:  Tumour Biol       Date:  2013-02-20

8.  Rapid attenuation of circadian clock gene oscillations in the rat heart following ischemia-reperfusion.

Authors:  Theodore A Kung; Oluwaseun Egbejimi; Jiajia Cui; Ngan P Ha; David J Durgan; M Faadiel Essop; Molly S Bray; Chad A Shaw; Paul E Hardin; William C Stanley; Martin E Young
Journal:  J Mol Cell Cardiol       Date:  2007-09-05       Impact factor: 5.000

9.  BHLHB2 controls Bdnf promoter 4 activity and neuronal excitability.

Authors:  Xueying Jiang; Feng Tian; Yang Du; Neal G Copeland; Nancy A Jenkins; Lino Tessarollo; Xuan Wu; Hongna Pan; Xian-Zhang Hu; Ke Xu; Heather Kenney; Sean E Egan; Helen Turley; Adrian L Harris; Ann M Marini; Robert H Lipsky
Journal:  J Neurosci       Date:  2008-01-30       Impact factor: 6.167

10.  Epigenetic repression of DNA mismatch repair by inflammation and hypoxia in inflammatory bowel disease-associated colorectal cancer.

Authors:  Robert A Edwards; Mavee Witherspoon; Kehui Wang; Kambiz Afrasiabi; Trang Pham; Lutz Birnbaumer; Steven M Lipkin
Journal:  Cancer Res       Date:  2009-07-28       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.